Immunosuppression facilitates the reactivation of latent papillomavirus infections

Journal of Virology

Volumn 88, Issue 1, 2014, Pages 710-716

  Maglennon, G A ^a,b   McIntosh, P B ^a   Doorbar, J ^a,c  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE (NADP)(PHOSPHORYLATING); VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; COTTONTAIL RABBIT PAPILLOMAVIRUS; DRUG TOLERABILITY; FEMALE; GENE DOSAGE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LOW DRUG DOSE; NONHUMAN; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RABBIT; RABBIT ORAL PAPILLOMAVIRUS; REMISSION; TONGUE DISEASE; VIRUS REACTIVATION; WEIGHT REDUCTION;

ANIMALS; IMMUNOSUPPRESSION; PAPILLOMAVIRUS INFECTIONS; RABBITS; VIRUS LATENCY;

EID: 84890876415     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02589-13     Document Type: Article

References (27)

1. Jamieson DJ, Duerr A, Burk R, Klein RS, Paramsothy P, Schuman P, Cu-Uvin S, Shah K. 2002. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am. J. Obstet. Gynecol. 186:21-27.
2. Moscicki AB, Ellenberg JH, Vermund SH, Holland CA, Darragh T, Crowley-Nowick PA, Levin L, Wilson CM. 2000. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch. Pediatr. Adolesc. Med. 154:127-134.
3. Ozsaran AA, Ates T, Dikmen Y, Zeytinoglu A, Terek C, Erhan Y, Ozacar T, Bilgic A. 1999. Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. Eur. J. Gynaecol. Oncol. 20: 127-130.
4. Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, Young M, Melnick S, Miotti P, Burk R. 1999. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)- positive and high-risk HIV-negative women. J. Natl. Cancer Inst. 91:226- 236.
5. Paternoster DM, Cester M, Resente C, Pascoli I, Nanhorngue K, Marchini F, Boccagni P, Cillo U, Ribaldone R, Amoruso E, Cocca N, Cuccolo V, Bertolino M, Surico N, Stratta P. 2008. Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant. Proc. 40:1877-1880.
6. Savani BN, Goodman S, Barrett AJ. 2009. Can. routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation? Clin. Cancer Res. 15:2219-2221.
7. Savani BN, Stratton P, Shenoy A, Kozanas E, Goodman S, Barrett AJ. 2008. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation-implications for screening and HPV vaccination. Biol. Blood Marrow Transplant. 14:1072-1075.
8. Veroux M, Corona D, Scalia G, Garozzo V, Gagliano M, Giuffrida G, Costanzo CM, Giaquinta A, Palermo I, Zappala D, Tallarita T, Zerbo D, Russo R, Cappellani A, Franchina C, Scriffignano V, Veroux P. 2009. Surveillance of human papilloma virus infection and cervical cancer in kidney transplant recipients: preliminary data. Transplant. Proc. 41:1191- 1194.
9. Gravitt PE. 2012. Evidence and impact of human papillomavirus latency. Open Virol. J. 6:198-203.
10. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD. 2005. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337:76-84.
11. Amella CA, Lofgren LA, Ronn AM, Nouri M, Shikowitz MJ, Steinberg BM. 1994. Latent infection induced with cottontail rabbit papillomavirus. A model for human papillomavirus latency. Am. J. Pathol. 144:1167- 1171.
12. Maglennon GA, McIntosh P, Doorbar J. 2011. Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology 414:153-163.
13. Stanley MA, Moore RA, Nicholls PK, Santos EB, Thomsen L, Parry N, Walcott S, Gough G. 2001. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine 19:2783-2792.
14. Zhang P, Nouri M, Brandsma JL, Iftner T, Steinberg BM. 1999. Induction of E6/E7 expression in cottontail rabbit papillomavirus latency following UV activation. Virology 263:388-394.
15. Hu J, Peng X, Cladel NM, Pickel MD, Christensen ND. 2005. Large cutaneous rabbit papillomas that persist during cyclosporin A treatment can regress spontaneously after cessation of immunosuppression. J. Gen. Virol. 86:55-63.
16. Harvey SB, Cladel NM, Budgeon LR, Welsh PA, Griffith JW, Lang CM, Christensen ND. 1998. Rabbit genital tissue is susceptible to infection by rabbit oral papillomavirus: an animal model for a genital tissue-targeting papillomavirus. J. Virol. 72:5239-5244.
17. Gratwohl A, Riederer I, Graf E, Speck B. 1986. Cyclosporine toxicity in rabbits. Lab. Anim. 20:213-220.
18. Petraitiene R, Petraitis V, Bacher J, Das SR, Parlow AF, Walsh TJ. 2001. Cyclosporine A-induced mammary hyperplasia and hyperprolactinemia in New Zealand White rabbits. Comp. Med. 51:430-435.
19. Jeklova E, Leva L, Jaglic Z, Faldyna M. 2008. Dexamethasone-induced immunosuppression: a rabbit model. Vet. Immunol. Immunopathol. 122: 231-240.
20. Christensen ND, Cladel NM, Reed CA, Budgeon LR, Welsh PA, Patrick SD, Kreider JW. 1996. Laboratory production of infectious stocks of rabbit oral papillomavirus. J. Gen. Virol. 77(Pt 8):1793-1798.
21. Doorbar J. 2013. Latent papillomavirus infections and their regulation. Curr. Opin. Virol. 3:416-421.
22. Maglennon GA, Doorbar J. 2012. The biology of papillomavirus latency. Open Virol. J. 6:190-197.
23. Cladel NM, Budgeon LR, Cooper TK, Balogh KK, Hu J, Christensen ND. 2013. Secondary infections, expanded tissue tropism, and evidence for malignant potential in immunocompromised mice infected with Mus musculus papillomavirus 1 DNA and virus. J. Virol. 87:9391-9395.
24. Ingle A, Ghim S, Joh J, Chepkoech I, Bennett Jenson A, Sundberg J. 2011. Novel mouse papillomavirus (MusPV) infection. Vet. Pathol. 48: 500-505.
25. Schulz E, Gottschling M, Ulrich RG, Richter D, Stockfleth E, Nindl I. 2012. Isolation of three novel rat and mouse papillomaviruses and their genomic characterization. PLoS One 7:e47164. http://dx.doi.org/10.1371 /journal.pone.0047164.
26. Doorbar J, Parton A, Hartley K, Banks L, Crook T, Stanley M, Crawford L. 1990. Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. Virology 178:254-262.
27. Christensen ND, Cladel NM, Reed CA, Han R. 2000. Rabbit oral papillomavirus complete genome sequence and immunity following genital infection. Virology 269:451-461.